Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL) had its price target lowered by analysts at Stifel Nicolaus from $36.00 to $32.00. They now have a "buy" rating on the stock.
Pleasing Signs As A Number Of Insiders Buy Zentalis Pharmaceuticals Stock [Yahoo! Finance]
Zentalis Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Progress
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Zentalis Pharmaceuticals to Highlight Preclinical Data Demonstrating that WEE1 Inhibitor Azenosertib Exerts Synergistic Anti-tumor Activity with KRAS(G12C) Inhibitors at AACR Annual Meeting 2024 [Yahoo! Finance]